芪苈强心胶囊联合沙库巴曲缬沙坦对慢性心力衰竭患者心功能的影响

摘要：目的：探讨芪苈强心胶囊联合沙库巴曲缬沙坦对慢性心力衰竭（Chronic Heart Failure，CHF）患者心功能的影响。方法：102例CHF患者随机分为：沙库巴曲缬沙坦组（对照组）和芪苈强心胶囊联合沙库巴曲缬沙坦组（观察组），分别给予沙库巴曲缬沙坦和沙库巴曲缬沙坦联合芪苈强心胶囊治疗六个月，观察患者显效率、有效率和左室舒张末期内径（left ventricular end-diastolic diameter, LVEDD）、左室收缩末期内径（left ventricular end-systolic diameter,LVESD）、左室射血分数（Left ventricular ejection,LVEF）、心输出量（Cardiac output，CO），NYHA II 级的改善率、血氨基末端B型脑钠肽前体（N-terminalpro-brain natriuretic peptide,NT-proBNP）、6分钟步行实验（6-min walk test,6-MWT）的变化。结果：两组患者治疗6个月后LVESD、LVEDD均显著低于治疗前（P ＜ 0.05），LVEF、CO均显著高于治疗前（P ＜ 0.05），但组间比较无显著性（P > 0.05）；沙库巴曲缬沙坦联合芪苈强心胶囊组显效率和治疗后NHYA II级显著高于沙库巴曲缬沙坦组，差异有显著意义（P ＜ 0.05）。治疗后8周、12周NT-proBNP显著低于治疗前（P ＜ 0.05），6-MWT显著高于治疗前（P ＜ 0.05），两组间比较差异无显著性（P > 0.05），治疗6个月后NT-proBNP显著低于对照组（P ＜ 0.05），6-MWT显著高于对照组（P ＜ 0.05）。结论：沙库巴曲缬沙坦联合芪苈强心胶囊能够进一步提高CHF患者NYHA分级和6分钟步行试验距离。

Effect of Qili Qiangxin Capsule Combined with Sacubitril/Valsartan on Cardiac Function in Patients with Chronic Heart Failure

ABSTRACT: Objective: To investigate the effect of Qili Qiangxin Capsule combined with Sacubitril/Valsartan on cardiac function in patients with chronic heart failure (CHF). Methods: 102 patients with CHF were randomly divided into two groups: Sacubitril/Valsartan group (control group) and Qili qiangxin capsule combined with Sacubitril/Valsartan group (observation group). Sacubitril/Valsartan and Sacubitril/Valsartan combined with Qili qiangxin capsule were given to the patients for six months respectively. The apparent efficiency, effective rate and Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), cardiac output (CO), NYHA II improvement rate, N-terminalpro-brain natriuretic peptide(NT-proBNP) and 6-minute walk test (6-MWT) were observed.Results: After 6 months of treatment, LVESD and LVEDD in both groups were significantly lower than those before treatment (P < 0.05), LVEF and CO were significantly higher than those before treatment (P < 0.05), but there was no significant difference between the two groups (P > 0.05). The significant efficiency and NHYA II level in the group of Sacubitril/Valsartan combined with Qili qiangxin Capsule were significantly higher than those in Sacubitril/Valsartan group. There was significant difference (P < 0.05). NT-proBNP in 8 and 12 weeks after treatment was significantly lower than that before treatment (P < 0.05), 6-MWT was significantly higher than that before treatment (P < 0.05), there was no significant difference between the two groups (P > 0.05), NT-proBNP in 6 months after treatment was significantly lower than that in the control group (P < 0.05), and 6-MWT was significantly higher than that in the control group (P < 0.05). Conclusion: Sacubitril/Valsartan combined with Qili qiangxin capsule can further improve the NYHA classification and 6-minute walking test distance of CHF patients.